Navigation Links
PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
Date:1/10/2011

y Advisor (2007-2010) for the U.S. Department of Health and Human Services (HHS).  In these positions, Dr. Fuerst led the development and acquisition of vaccines and biotherapeutic products for biodefense and other emerging public health threats, including anthrax, smallpox, botulism, and pandemic flu. During his tenure at HHS, he helped establish the Biomedical Advanced Research and Development Authority (BARDA) and oversaw the planning, implementation, and monitoring of medical countermeasure development and acquisition, while managing a budget of approximately $3.0 billion.

Previously, Dr. Fuerst served as Executive Director of Corporate Development at Sanofi Pasteur, Inc., where he oversaw the scientific and business transactions for vaccines and immunotherapeutic products for infectious diseases and cancer, and played a key role in establishing the company's biodefense initiative post 9/11.  He also led a collaborative R&D group to develop a next generation anthrax vaccine in response to the National Institute of Health's Request for Proposal.  Prior thereto, he was Vice President, Research and Development, at Genelabs Technologies, and a scientific founder and Director of Molecular Genetics, at MedImmune.  He also served as a senior fellow at the National Institutes of Health, NIAID, in Bethesda, MD.  Dr. Fuerst holds a B.A. in Biochemistry from the University of California at Berkeley, a Ph.D. in Molecular Genetics from Cornell University, and a MBA in Science, Technology, and Innovation from the George Washington University.

Ms. Linna, who was recently appointed to the position of Vice President of Program Management, brings more than 23 years of experience in drug development, with extensive experience building global project management offices in the biotechnology and pharmaceutical industries.  Most recently, she served as the Executive Director of Project Management at Novavax Inc., with global project mana
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
2. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
3. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
4. PharmAthene Announces Pricing of $15 Million Public Offering
5. PharmAthene Announces Proposed Common Stock Offering
6. PharmAthene Announces $3.9 Million Registered Direct Offering
7. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
8. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
9. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
10. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
11. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... The science of light and how it ... than 200 primary students in a traveling program organized ... Otago Physics Department and funded by an SPIE ... the university’s OSA/SPIE Student Chapter visited six primary schools ... from small, rural schools hands-on lessons in optics and ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3
... , MALVERN, Pa. and WALTHAM, Mass., Nov. ... find that the leading driver of antibiotic selection in ... and gram-negative pathogens. Due to the variety of organisms ... that they look primarily for agents that provide appropriate ...
... , MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ... a randomized Phase 2B study of AEG35156, a targeted ... , The study, entitled "An Open-Label Randomized Phase 2 ... AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin ...
... ... Consortium (IGSC) to Coordinate Best Practices in Risk Reduction ,Five Member Companies Represent ... ... leading gene synthesis companies today announced agreement that they will apply a common screening ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... reprogrammed stem cells from a key organ in the immune ... regeneration. Their research shows that it is possible to ... genetic modification. Researchers, who used rat models, grew ... our immune systems in the laboratory using conditions for ...
... destroys brain cells and their connections (called synapses), causing ... hobbies and daily life. Symptoms can be alleviated, in ... States as Namenda), which is currently FDA-approved to treat ... Stuart A. Lipton, M.D., Ph.D., Director of the Del ...
... Tech College of Engineering researchers have received a $60,000 ... occurring microbes can best be used to eat away ... Their choice of weapon: Geometry. Fueled by oxygen, ... of crude oil without the use of additional chemicals. ...
Cached Biology News:Stem cell versatility could help tissue regeneration 2Study explains why Alzheimer's drug is both safe and effective 2Does the shape of crude oil remnants impact rate of biodegradation? 2Does the shape of crude oil remnants impact rate of biodegradation? 3
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
HSV-1 gE Envelope Protein (9H3)...
... functionally defined by their capacity to self ... multiple specialized progenitor cells, which can commit ... stem cells (NSCs) are capable of differentiating ... and oligodendrocytes. During the isolation and expansion ...
Lineage cocktail 1 (lin 1) 50 tests...
Biology Products: